GenMont Biotech, Inc.

GenMont Biotech, Inc.

TTWSE:3164
16.80
TWD
+0.15
(+0.90%)
0.69EPS
19.74P/E
1.37BMarket Cap
GenMont Biotech, Inc.
TWSE:3164
(Taiwan Stock Exchange)

Recent

price

16.80

P/E

ratio

19.74

div

yld

- -

ROIC.AI

2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
TTM
TWD
9.71
5.4
4.12
5.07
8.51
6.01
6.08
4.28
4.57
3.89
3.7
4.96
4.27
3.68
4.45
4.65
4.45
Revenue per Share
2.79
0.72
0.52
0.51
-5.82
-1.1
-2.65
0.51
1.78
0.65
0.69
1.31
0.66
0.38
0.66
0.66
0.81
Basic EPS, GAAP
3.18
0.62
-0.45
1.47
-1.47
-0.33
0.14
0.55
-2.47
-3.59
-0.24
-0.06
0.76
-0.01
0.92
0.81
0.99
Free Cash Flow per Basic Share
1.01
2.46
1.18
0.5
- -
- -
- -
- -
- -
1.5
0.81
0.7
1.1
0.7
0.23
0.8
- -
Dividend per Share
12.98
12.75
14.05
13.65
17.97
16.87
14.39
15.04
16.77
15.57
15.4
15.94
15.65
15.22
15.63
15.47
15.23
Book Value per Share
12.74
12.49
13.83
13.5
14.12
13.94
14.23
14.9
16.66
15.57
15.39
15.93
15.64
15.19
15.6
15.45
15.21
Tangible Book Value per Share
53
53
55
61
66
89
89
89
89
89
88
86
86
86
87
86
86
Basic Weighted Avg Shares
515
286
227
309
565
535
541
381
407
346
325
428
369
318
385
401
382
Sales/Revenue/Turnover
30.45
-5.81
-13
18.42
-25.57
-8.6
-3.35
28.65
30.21
22.17
21.64
29.99
16.33
2.43
10.41
14.57
9.5
Operating Margin (%)
22
23
20
17
104
96
88
40
27
21
21
21
50
65
72
67
68
Depreciation Expense
148
38
28
31
-386
-98
-236
46
158
57
61
113
57
33
57
57
69
Net Income, GAAP
4.96
12.44
41.12
16.19
- -
- -
- -
- -
20.83
24.23
21.64
21.39
28.37
20.35
26.22
24.65
26.92
Effective Tax Rate (%)
28.67
13.33
12.53
10
-68.4
-18.33
-43.63
11.98
38.87
16.59
18.72
26.44
15.46
10.37
14.86
14.26
18.1
Profit Margin (%)
831
1,003
653
664
280
313
342
404
1,022
595
501
442
361
319
402
426
398
Working Capital
- -
485
- -
- -
- -
- -
- -
- -
- -
31
32
31
33
54
83
78
81
LT Debt
738
905
862
837
1,597
1,500
1,280
1,371
1,563
1,448
1,482
1,524
1,497
1,449
1,480
1,450
1,429
Total Equity
21.34
-1.36
-1.4
3.62
- -
- -
- -
- -
6.57
3.83
3.68
6.29
2.82
0.36
1.91
2.73
1.34
Return on Invested Capital (%)
20.2
4.19
3.06
3.82
- -
- -
- -
- -
10.79
3.83
4.15
7.63
4.34
2.92
4.48
4.39
5.42
Return on Capital (%)
22.45
5.52
3.7
3.64
-31.72
-6.33
-16.97
3.49
11.18
4
4.49
8.36
4.18
2.47
4.29
4.26
5.43
Return on Common Equity (%)

Capital Structure

TWD

•

in mil. unless spec.
Dec'25
Mar'26
Jun'26
ST Debt
33
40
52
LT Borrowings
45
43
43
LT Finance Leases
33
37
37
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
86
86
86
Market Capitalization
1,578
1,557
1,368

Working Capital

TWD

•

in mil. unless spec.
Dec'25
Mar'26
Jun'26
Total Current Assets
555
579
552
Cash, Cash Equivalents & STI
433
457
425
Accounts Receivable, Net
46
45
51
Inventories
70
69
68
Total Current Liabilities
130
209
154
Payables & Accruals
- -
- -
- -
ST Debt
33
40
52
Deferred Revenue
- -
- -
- -

Growth Rates

TWD

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
-0.06%
-0.41%
-2.02%
Free Cash Flow
-1,051.35%
-2,012.79%
-12.21%
Net Income, GAAP
27.77%
13.51%
-0.09%
Sales/Revenue/Turnover
-1.33%
5.86%
4.11%
Total Cash Common Dividend
- -
37.3%
247.82%

Quarterly Revenue

TWD

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
116
94
84
91
385
2025
99
112
89
101
401
2026
89
103
- -
- -
- -

Quarterly Earnings Per Share

TWD

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
0.4
0.17
0.07
0.02
0.66
2025
0.19
-0.1
0.29
0.29
0.66
2026
0.05
0.18
- -
- -
- -

Quarterly Dividends Per Share

TWD

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
0.23
2025
- -
- -
- -
- -
0.8
2026
- -
- -
- -
- -
- -
Business
GenMont Biotech Incorporation specializes in the research, development, manufacture, and sale of functional probiotic supplements and health care food products in Taiwan. Its core offerings include functional probiotic raw materials, probiotic capsules, powders, tablets, liquid probiotic products, and specialized probiotic formulas such as Gu-Tang-Le ADR-1, Dental-Lac Troches, and eN-Lac APF probiotic capsules. The company provides original formula design and manufacturing services alongside equipment manufacturing for health care foods. GenMont also engages in clinical trials and cooperative research to develop and validate new probiotic and nutraceutical products. Founded in 2000 and headquartered in Tainan City, Taiwan, the company operates primarily within Taiwan's biotech and health supplement industry, targeting health-conscious consumers and healthcare providers. Key recent developments include completion of an equity buyback plan in mid-2025 and ongoing product innovation in functional probiotics, strengthening its market position with enhanced proprietary probiotic strains and expanded product portfolios. GenMont maintains a focus on increasing its R&D capabilities and clinical validation to support new product launches and strategic business expansions in the probiotics sector. The company continues to emphasize OEM and ODM services for functional probiotic supplements with diversified delivery forms and formulations tailored to meet consumer demands and health trends in Asia. This strategic orientation consolidates its stature as a leading probiotics manufacturer in East Asia.